CURRICULUM VITAE

NAME George Warren Booz, Ph.D., F.A.H.A.

CITIZENSHIP USA

ADDRESS

University of Mississippi Medical Center
Department of Pharmacology and Toxicology
2500 North State Street
Jackson, MS 39216-4505

- TEL: 601-984-4401
- FAX: 601-984-1637
- Email: gbooz@umc.edu

EDUCATION AND POST-GRADUATE TRAINING

B.S. in Biology	1972 – 1976	St. Joseph's University Philadelphia, PA
M.S. in Physiology	1977 – 1981	University of Pennsylvania Philadelphia, PA
Computer Science	1983 – 1986	Drexel University Evening College Philadelphia, PA
Ph.D. in Pharmacology	1986 – 1990	Thomas Jefferson University Philadelphia, PA
Postdoctoral Fellow	9/90 – 6/94	Weis Center for Research Geisinger Clinic Danville, PA

NON-FACULTY POSITIONS

Associate Scientist	7/94 – 5/96	Weis Center for Research Geisinger Clinic
Research Scientist-1	6/96 – 6/97	Weis Center for Research Geisinger Clinic

FACULTY POSITIONS

Instructor	7/97 – 6/98	Department of Cellular and Molecular Physiology Pennsylvania State University College of Medicine Weis Center for Research
Assistant Professor	6/98 – 5/99	Department of Cellular and Molecular Physiology Pennsylvania State University Coll. of Med., Weis Center for Research
Assistant Professor	5/99 – 9/02	Department of Internal Medicine Texas A & M University System HSC College of Medicine Cardiovascular Research Institute Division of Molecular Cardiology
Research Physiologist (WOC)	09/00 – 10/08	The Central Texas Veterans Health Care System

Assistant Professor	9/02 – 10/08	Department of Internal Medicine Texas A & M University System HSC College of Medicine Cardiovascular Research Institute Division of Molecular Cardiology
Assistant Professor (cross-appointment)	5/03 – 1/06	Department of Medical Physiology Texas A & M University System HSC College of Medicine
Member	6/03 – 10/08	Pulmonary and Critical Care Medicine Scott & White Hospital and Clinics The Texas A & M University System HSC College of Medicine
Member	10/03 – 10/08	Graduate Faculty Texas A&M Univ. System HSC College of Medicine Medical Sciences Program
Assistant Professor (Adjunct)	10/05 – 10/06	Department of Biology University of Mary Hardin-Baylor Belton, TX
Associate Professor	11/3/08 – present	Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, School of Medicine
Member	1/13/09 – present	Graduate Faculty The University of Mississippi Medical Center, School of Graduate Studies in the Health Sciences

RESEARCH SUPPORT

Submitted

NIH: 1R01HL137883-01
Transition from Endothelial Inflammation to Diastolic Dysfunction in HFpEF
07/01/2017 - 06/30/2022
PI: George Booz, PhD
Total Requested: $1,906,250.00

NIH: 1R01HL139569-01
Targeting inflammation in HFpEF cardiac remodeling
12/01/2017 - 11/30/2022
PI: George Booz, PhD
Total Requested: $1,937,500.00

Completed

7/1/08 – 6/30/14	National Heart, Lung, and Blood Institute *Regulation of IL-6-Type Cytokine Cardioprotective Signaling in the Ischemic Heart* Principal Investigator: George Booz Co-Investigators: Roy Duhé, Mazen Kurdi Total Direct Costs: $1,225,676
8/1/09 – 7/31/11	National Heart, Lung, and Blood Institute Recovery Act Administrative Supplement to RO1: Postdoctoral Fellow Principal Investigator: George Booz

	Total Direct Costs: $178,800
5/1/09 – 4/30/10	Intramural Research Support Program *Antioxidant Hydrogel POSS-Catechin Nanocomposites for Stem Cell Cardiac Survival* Principal Investigator: George Booz Total Direct Costs: $25,000
10/1/08 – 9/30/10	ProStem Biotech Inc. *Improving the Therapeutic Potential of Umbilical Cord Blood Stem Cells for Cardiac Repair* Principal Investigator: George Booz Co-Investigator: Mazen Kurdi Total Direct Costs: $240,000 Amount paid: $64,000
6/1/07 – 5/31/08	S&W Research Foundation Grant *Role of JAK signaling in diabetic cardiomyopathy* Principal Investigator: George Booz Co-Investigators: Syed Naqvi, Roy Duhe Total Direct Costs: $40,000
11/17/06 – 11/16/07	S&W Research Foundation Grant *Role of Calcitonin-Gene Related Peptide in Ischemia/Reperfusion Injury* Principal Investigator: Khurshed Katki Co-Investigators: Mazen Kurdi, George W. Booz Total Direct Costs: $40,000
7/1/05 – 6/30/06	S&W Research Foundation Grant *Regulation of Non-Small Cell Cancer Apoptosis by Interferon-γ* Principal Investigator: George Booz Co-Investigators: Richard E. Winn, Gagan Prakash Total Direct Costs: $39,988
7/1/04 – 6/30/06	American Heart Association, Texas Affiliate *Role of STAT3 in Defining IL-6 Signaling in Myocardial Infarction* Principal Investigator: George W. Booz Total Direct Costs: $124,000
8/3/03 – 8/2/05	VA VISN17 *STAT3 Transcriptional Regulation of Cardiac Myocyte Growth* Principal Investigator: George W. Booz Total Direct Costs: $100,000
3/1/04 – 2/28/05	S&W Research Foundation Grant *Antioncogenic Potential of GRIM-19 in Human Non-Small-Cell Lung Cancer Cells* Principal Investigator: Richard E. Winn Co-Investigators: George Booz, Steve Maxwell, Christopher Spradley Total Direct Costs: $40,000
10/1/03 – /30/04	S&W Research Foundation Grant *Role of STAT Transcription Factors in Apoptosis of Human Non-Small-Cell Lung Cancer Cells* Principal Investigator: George W. Booz Co-Investigator: Nikhat Salamat Total Direct Costs: $40,000
7/1/99 – 6/30/03	National Institutes of Health (HL44883) Regulation of Cardiac Hypertrophy by Angiotensins.

Principal Investigator: Kenneth M. Baker
Co-Investigators: David E. Dostal, George W. Booz
Total Direct Costs: $980,000

7/1/98 – 6/30/03 National Heart, Lung, and Blood Institute (HL58439)
Novel Signaling Pathways for Angiotensin II in The Heart
Principal Investigator: Kenneth M. Baker
Co-Investigator: George W. Booz
Total direct costs: $999,457

7/1/96 – 6/30/98 American Heart Association, Pennsylvania Affiliate
Role of the AT2 Receptor in Angiotensin II-Induced Hypertrophy of Cardiac Myocytes
Principal Investigator, George W. Booz
Total Direct Costs: $70,000

9/1/94 – 8/31/95 American Heart Association, Pennsylvania Affiliate
Relative Contribution of Protein Kinase C Isozymes to Hypertrophic Growth of Cardiac Myocytes
Principal Investigator, George W. Booz
Total Direct Costs: $35,000
Total Direct Costs: $25,000

7/1/91 – 6/30/94 National Heart, Lung, and Blood Institute
National Research Service Award, HL08477
Mechanisms of Angiotensin-Induced Cardiac Hypertrophy
Total Direct Costs: $81,200

PUBLIC AND PROFESSIONAL SERVICE

Grant Reviewer (Ad hoc)

VA Merit Review Proposals, 1994 – 2000
U.S. Civilian Research & Development Foundation (CRDF), 2005
AIBS: US Army Medical Research and Materiel Command (USAMRMC), 2005 - 2007
FAMRI Center of Excellence Award, 2006
FAMRI Center of Excellence Award, 2006
FAMRI Re-Review, 2007
FAMRI Center of Excellence Award (Re-Review), 2012
FAMRI Richmond Center of Excellence progress report, 2013
FAMRI Richmond Center of Excellence progress report, 2014
FAMRI Richmond Center of Excellence progress report, 2015
National Medical Research Council (Singapore), 2006
The National Research Program on Cardiovascular Diseases (Inserm/French National Institute for Health and Medical Research) and The French Society of Arterial Hypertension, 2007
GENOPAT Program - Molecular Pathophysiology: From Rare to Common Diseases, Proposals submitted to French National Research Agency (Inserm/French National Institute for Health and Medical Research) in association with the French Association against Myopathies, 2009
Italian Ministry of Health, Directorate for Health and Technologies Research, 2009
Italian Ministry of Health, 'Young Italian Researchers Call', 2010
Italian Ministry of Health, 2011,2012,2013
French National Research Agency, “BlueSky and Young Researchers Programmes” 2011
French National Research Agency, Call for projects: White - SVSE 1 - Physiology, pathophysiology, public health, 2012

Pathophysiology Section of the French National Research Agency in the Exploratory and Emerging Research Department, 2013
French National Research Agency, generic call for proposals 2014: pre-proposal evaluation
CARIPARO Foundation, 2012
AIBS/FAMRI Clinical Innovator Award, 2012, 2013
Genomics and Immunology Research Laboratory within the USDA Beltsville Human Nutrition Research Center, project plan "Health promoting roles of food bio-active phenolic compounds on obesity-altered heart and kidney functions and physiology", 2013
The South Dakota State University College of Pharmacy, 2014
AHA Collaborative Science Award Letter of Intent, 2014
Italian Ministry of Health - National Call Biomedical Research, 2014
FY15 Peer Reviewed Medical Research Program (PRMRP) for the Department of Defense Congressionally Directed Medical Research Programs - Discovery Cardiovascular Health

Grant Review Panels

NHLBI Program Project Review Panel, Spring 2004
NHLBI Program Project Review Panel, Sept. 2004,
NHLBI Program Project Review Panel, Jan. 2005, Sept. 2005
NHLBI Program Project Review Panel, Feb. 2006, Sept. 2007
American Institute of Biological Sciences -
FAMRI (Flight Attendant Medical Research Institute):

- Panel - Molecular basis of cancers associated with second hand smoke: 2005
- Panel - Molecular basis of diseases (non-cancer) associated with second hand smoke: 2004, 2006, 2007
- Panel - Cardiovascular Diseases: 2008

American Heart Association
Cardiac Biology/Regulation - Basic & Clinical / Translational:
Region 3, Spring 2009 & Spring 2010
Region 2 and 3, Fall 2010
Region 2 and 3, Spring 2011
Region 2 and 3, Fall 2011
Region 2 and 3, Spring 2012
Cardiac Bio BSc 1: Fall 2012
Cardiac Bio Reg - BSci 3: Spring, 2013 (co-chairperson)
Cardiac Bio Reg - BSci 3: Fall, 2013 (co-chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2014 (co-chairperson)
Cardiac Bio Reg - BSci 6: Fall, 2014 (co-chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2015 (chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2016 (chairperson)
Cardiac Bio Reg - BSci 3: Fall, 2016 (chairperson)
National Heart, Lung, and Blood Institute
NHLBI P30 Review (ARRA funds), 2009
NHLBI Special Emphasis Panel – Research Centers at Minority-Serving Institutions
Basic Research in Calcific Aortic Valve Disease (R01); April 4, 2012.
NHLBI P50 Review - RFA-NHLBI Research Centers at Minority Serving Institutions - Phase II, December 2012
FY15 Peer Reviewed Medical Research Program (PRMRP) for the Department of Defense Congressionally Directed Medical Research Programs: Peer review panel - Programs in cardiovascular health, Fall 2015

Site Visits

2010 FAMRI Julius B. Richmond Center of Excellence at the American Academy of Pediatrics, Elk Grove Village, Illinois

Committees

Institutional Review Board (Human Studies Subcommittee) of the Central Texas Veterans Health Care System, 2000 – 2006
Publications Committee, Council for High Blood Pressure Research (Ad Hoc), 2003 – 2006
Radioisotope Protocol Review Committee of the Central Texas Veterans Health Care System, 2004 – 9/25/08
Subcommittee on Research Safety of the Central Texas Veterans Health Care System, 2004 – 2008; Chair, 10/1/06 – 9/25/08
Research and Development (R&D) Committee of the Central Texas Veterans Health Care System, 2006 – 9/25/08
Public Affairs Committee (Alternate), The American Physiological Society, 2005 – 2006
Institutional Biosafety Committee (*Ex-Officio*), Texas A&M University, 2006 – June 2007
Institutional Biosafety Committee, Texas A&M University, June 2007 – 9/25/08
Admissions Committee for the Graduate Program in Pharmacology and Toxicology, The University of Mississippi Medical Center, 2010 – 2012
Graduate Program Committee, Dept. Pharmacology, The University of Mississippi Medical Center, 2012 – present
Faculty Search Committee, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, 2010
Faculty Recruitment Committee, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, 2012 – 2016 (Chair)
Pharmacology Education/Graduate Curriculum Committee, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, 2010 - 2012
Professional Education Committee, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, 2012 – 2016
Strategic Planning Committee (Department of Pharmacology and Toxicology), 2017 – present
SFRBM Nominations/Leadership Development Committee, 2010 – present

Memberships

American Heart Association, 1991 - present
American Stroke Association, 2003 - present
Council for High Blood Pressure Research, 2003 - present
Society for Free Radical Biology and Medicine, 2009 - present
Biochemical Society, 2015 - present
Mount Desert Island Biological Laboratory,
Associate, 1977 – 1990
Full, 1990 – present
American Physiological Society, 1991 - 2016
American Society for Cell Biology, 2004 - 2016
International Society for Heart Research, 1994 - 2016
Heart Failure Society of America, 2004 - 2016
European Cytokine Society, 2012 - 2014
American Society of Hypertension, 2003 – 2011
The Texas Chapter of the American Society of Hypertension, 2003 - 2008
New York Academy of Sciences, 1995 - 2011
American Thoracic Society, 2004 – 2011

Member

2009 – 2015	Center for Excellence in Cardiovascular Renal Research, University of Mississippi Medical Center
2010 – 2014	Women's Health Research Center University of Mississippi Medical Center
2013 – 2014	Mississippi Center for Heart Research at UMMC

EDITORIAL DUTIES

Associate Editor: 2013 – present	Journal of Cardiovascular Pharmacology
Associate Editor: 2014 – present	Frontiers in Cardiovascular Medicine
Reviews Editor: 2015 – present	European Journal of Pharmacology
Senior Editor: 2009 – 2013	Congestive Heart Failure
Section Editor: 2007 – 2013	Congestive Heart Failure: Translational Research
Guest Editor: 2007	Journal of Cardiovascular Pharmacology Review Series - *Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond*
2010	Journal of Cardiovascular Pharmacology Review Series - *Novel Drugs Targeting Hypertension: A Follow Up*
2011	Congestive Heart Failure Review Series - Mitochondria and Heart Failure

Editorial Boards:

2003-present	Hypertension
2004-present	Journal of Cardiovascular Pharmacology
2005-2013	Congestive Heart Failure
2008-2012	Cardiovascular Research
2014-present	Cardiovascular Research
2009-present	Free Radical Biology and Medicine
2013-present	European Journal of Pharmacology
2015-present	Clinical Science

Ad Hoc Reviewer

Hypertension, **Journal of Molecular and Cellular Cardiology**, Circulation, Journal of Clinical Investigation, Circulation Research, American Journal of Physiology: Heart and Circulatory Physiology, American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, Journal of Applied Physiology, Journal of Cardiovascular Pharmacology, Expert Opinion on Emerging Drugs, The International Journal of Biochemistry and Cell Biology, American Journal of Hypertension, Molecular and Cellular Biochemistry, Regulatory Peptides, Journal of the American College of Cardiology, Cardiovascular Research, Biochemical Pharmacology; Acta Pharmacologica Sinica, American journal of Pathology; Congestive Heart Failure; American Journal of Physiology: Cell Physiology; Physiological Genomics; American Journal of Physiology: Endocrinology and Metabolism; British Journal of Pharmacology; Endocrine; Clinical and Experimental Pharmacology and Physiology; Endocrinology; Free Radical Biology and Medicine; Apoptosis; Cardiovascular Drugs and Therapy; Experimental Cell Research; European Journal of Pharmacology; Phytotherapy Research; Experimental Gerontology;

Experimental Lung Research; Circulation: Heart Failure; Journal of Cellular Physiology; Biomedical Materials; PLOS ONE; European Journal of Heart Failure; JAK STAT, Journal of the Saudi Heart Association; Pharmacological Research; BBA - Molecular Cell Research; Expert Opinion On Pharmacotherapy; Environmental Toxicology and Pharmacology.

Hypertension - Proceedings of the Inter-American Society of Hypertension, 2003-2008
Hypertension - Proceedings of the Council for High Blood Pressure Research, 2003-2008
AHA Abstract Reviewer – Scientific Sessions 2004 - 2010
Abstract Reviewer –

- 16th Annual Meeting of the Society for Free Radical Biology and Medicine (SFRBM), 2009
- 17th Annual Meeting of the Society for Free Radical Biology and Medicine and Society for Free Radical Research International XV Biennial Meeting, 2010
- SFRBM's 18th Annual Meeting, 2011
- SFRBM's 19th Annual Meeting, 2012
- SFRBM's 20th Annual Meeting, 2013
- SFRBM's 21th Annual Meeting, 2014
- SFRBM's 22th Annual Meeting, 2015
- Joint Meeting of the European Society of Hypertension and International Society of Hypertension, 2014

PRESENTATIONS

1990 FASEB, *N-Carbobenzoxy-glycyl-L-phenylalaninamide Inhibits Both Basal and Contraction-Initiated 2-Deoxyglucose Uptake by Frog Muscle* (Seminar)

1992 FASEB, *Angiotensin II Binding Sites on Hepatocyte Nuclei* (Poster)

1993 Weis Center, *Role of PKC in the Mitogenic Effect of AII on Rat Cardiac Fibroblasts* (Seminar)

1994 Weis Center, *Involvement of Protein Kinase C and Calcium in Angiotensin II-Induced Mitogenesis of Cardiac Fibroblasts* (Seminar)

APS Conference, Signal Transduction and Gene Regulation, San Francisco, *Role of Protein Kinase C in Angiotensin II-Induced Mitogenesis of Neonatal Rat Cardiac Fibroblasts* (Poster)

1995 Weis Center, *Angiotensin II-Induced Cardiac Hypertrophy: A Role for the Type II Receptor?* (Seminar)

Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, *AT2 Receptor Blockade Augments Angiotensin II-Induced Cardiomyocyte Hypertrophy* (Seminar)

Dept. of Medical Pharmacology and Toxicology, Texas A&M University School of Medicine, *Role of Angiotensin II in Cardiac Hypertrophy and Remodeling* (Seminar)

1997 Dept. of Physiology, University of Florida, School of Medicine, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)

Weis Center, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)

College of Pharmacy, Division of Pharmacology and Experimental Therapeutics, University of Kentucky, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)

Children's Hospital Medical Center, Division of Pulmonary Medicine, Allergy, and Clinical Immunology, University of Cincinnati, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)

1998 H. Lee Moffitt Cancer Center and Research Institute, *Cardiac Actions of Angiotensin II* (Seminar)

2001 American College of Cardiology, Annual Scientific Session
Angiotensin II modulates gp130 signaling in cardiac myocytes by tyrosine phosphatase activation (Poster).

2001 Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research*, Endothelin-1 inhibits activation of the LIF receptor in cardiomyocytes* (Poster).

2003 AHA Scientific Conference on Molecular Mechanisms of Growth, Death and Regeneration in the Myocardium: Basic Biology and Insights into Ischemic Heart Disease and Heart Failure, *Role for β-arrestins, but not GRKs, in angiotensin II-induced internalization of AT_1* (Poster).

2004 American College of Cardiology, Annual Scientific Session,
Rescue of Internalization-Impaired *Angiotensin II AT1 Mutants by β-Arrestin Overexpression* (Poster).

2004 Heart Failure Society of America, 8th Annual Scientific Meeting
Molecular Mechanisms of IL-6-Related-Cytokine STAT3 Regulation in Cardiac Myocytes (Poster).

2004 Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research
The Anti-Inflammatory Agent Parthenolide has Differential and Independent Effects on Jak-STAT and ERK Signaling in Cardiac Myocytes (Poster).

2004 American Society for Cell Biology
Interferon-γ has a Potent Cytostatic Effect via STAT1 Activation on the A549 Human Lung Cancer Cell Line (Poster)

2005 Heart Failure Society of America, 9th Annual Scientific Meeting
Parthenolide induces oxidative stress in cardiomyocytes: Differential activation of mitochondrial and NADPH oxidases (Poster).

2005 University of Mississippi Medical Center, Department of Physiology & Biophysics
Making the Best of IL-6-Type Cytokines in the Stressed Heart: From STAT3 to SOCS3 to ROS.

2007 XIX World Congress of the ISHR Bologna (Italy)
Oxidative stress blocks activation of JAK-STAT signaling in cardiac myocytes (Poster).

2007 Department of Cell & Developmental Biology and Anatomy, School of Medicine University of South Carolina
JAK-STAT Signaling in the Heart – Novel Insights into Regulation

2007 The 6th Annual Symposium: The Cutting Edge – Cardiology for the Future, Long Beach Memorial Medical Center, Long Beach, California
PARP Inhibitors in Heart Failure: Translational Medicine in Progress

2008 University of Mississippi Medical Center, Department of Pharmacology and Toxicology
JAK-STAT Signaling in the Injured and Failing Heart

2008 TTUHSC School of Pharmacy, Department of Pharmaceutical Sciences
JAK-STAT Signaling in the Injured and Failing Heart

2009 University of Mississippi Medical Center, SURE Seminar, *Mending a Broken Heart: New Approaches to Heart Failure Prevention or Reversal*

2010 University of Mississippi Medical Center, Department of Physiology and Biophysics, *Hydrogels as a Platform for Stem Cell Delivery to the Heart*

2010 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, *Can the protective actions of JAK-STAT in the heart be exploited*

therapeutically?

2010 University of Mississippi Medical Center, Department of Biochemistry, *Uncovering the Versatility of STAT3 in Endothelial Cells*.

2011 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, Work In Progress 2011: Understanding JAK-STAT in the Heart

2012 Department of Pharmacology, University of Mississippi School of Pharmacy, *Redox-Sensitivity of STAT3: Implications for Heart Failure*

2012 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, *Redox-Sensitivity of STAT3: Implications for Heart Failure*

2012 Division of Cardiology, Department of Medicine, The Johns Hopkins University, Redox-Sensitivity of STAT3: Implications for Heart Failure

By members of the lab:

2004 CHEST (American College of Chest Physicians)
Activation of STAT1 BY IFN-γ Inhibits Growth of Human Non-Small Cell Lung Cancer Cells (Poster).

2005 CHEST (American College of Chest Physicians)
Role of STAT1 in the Permissive Effect of Interferon-γ on FAS-Induced Apoptosis of Non-Small Cell Lung Cancer Cells

2005 *XXVIIth Annual Meeting of the North American Section of the International Society for Heart Research New Orleans, LA May 12 - 15, 2005 "Cardiovascular Disease and Health"*. Anti-inflammatory parthenolide inhibits JAK1 activation in cardiac myocytes but induces oxidative stress (Poster).

2006 ATS International Conference in San Diego, California, May 19th-24th. Role for STAT3 in Apoptosis Signaling by Interferon-γ in Human Nonsmall Cell Lung Cancer A549 Cells (Poster).

2010 High Blood Pressure Research 2010 Scientific Sessions, Washington D.C. Nitroxyl activates redox-sensitive stress signaling in endothelial cells and has anti-inflammatory actions (Poster; Carlos Zgheib).

2010 High Blood Pressure Research 2010 Scientific Sessions, Washington D.C. PP2A plays a critical role determining the endothelial cell gene expression profile of leukemia inhibitory factor (LIF). (Oral; Carlos Zgheib).

2010 ASCB 50th Annual Meeting, Philadelphia, PA. Sodium Selenate Enhances Endothelial Cell STAT3 Tyrosine Phosphorylation and DNA Binding. (Poster; Hani Alturkmani/ Carlos Zgheib).

2011 EB2011, Washington, DC. Transient Receptor Potential Type C Channels Play a Critical Role in Angiogenesis (Poster; Fouad Zouein).

2012 EB2012, San Diego, CA, DUAL ROLE OF STAT3 IN HYPERTENSION-INDUCED CARDIAC REMODELING (Poster; Fouad Zouein).

2012 CHBPR 2012, Washington, DC. STAT3 Affects Myofibrillar Structure and Its Loss May Contribute to Heart Failure in Hypertension (Oral; Fouad Zouein).

2012 CHBPR 2012, Washington, DC. Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling is Redox-Sensitive. (Poster; Carlos Zgheib).

2013 CHBPR 2013, New Orleans, LA. Role of STAT3 in Collagen Deposition and Organization in the Normal and Hypertensive Heart (Poster; Fouad Zouein).

2015 AHA's Council on Hypertension 2015 Scientific Sessions conference in Washington, D.C. Importance of the C-Terminal Transactivation Domain of STAT3 in Hypertension-Induced Cardiac Hypertrophy (Oral; Fouad

Zouein).

HONORS AND AWARDS

1972 - 1976	Dean's List, St. Joseph's University
1972 - 1976	Presidential Scholarship, St. Joseph's University
1977 - 1980	National Research Service Award University of Pennsylvania
1983 - 1986	Dean's List, Drexel University
1986 - 1987	Foerderer Fellow, Thomas Jefferson University
1988	Summer Fellowship American Heart Association, Maine Chapter
1988 - 1989	Speck Fellowship, Thomas Jefferson University
1988 & 1977	Student Scholarship Mt. Desert Island Biological Laboratory
1989 - 1990	University Fellowship Thomas Jefferson University
1990	Fellowship Mt. Desert Island Biological Laboratory
1990	Elected Member Mt. Desert Island Biological Laboratory
2003	Editorial Board, Hypertension
2004	Top Ten Hypertension Reviewer
2004	Fellow of the American Heart Association/American Stroke Association
2004	Editorial Board, Journal of Cardiovascular Pharmacology
2005 – 2006	Adjunct Assistant Professor of Biology, Mary Hardin Baylor University
2005	Editorial Board, Congestive Heart Failure
2008	Consulting Editor/Editorial Board, Cardiovascular Research
2009	Editorial Board, Free Radical Biology and Medicine
2009	Excellence in Research Award at the University of Mississippi Medical Center, Bronze Level
2010	Excellence in Research Award at the University of Mississippi Medical Center, Gold Level
2011	Cardiovascular Research, Certificate of Appreciation (100 manuscripts)
2012	Hypertension, Certificate of appreciation as a top reviewer
2013	F1000Prime Faculty Member (Cardiovascular Pharmacology)
2013	Hypertension, Certificate of appreciation as top reviewer
2013	HBPR 2013, Co-chair of session: Cardiac Hypertrophy and Dysfunction
2013	Editorial Board, European Journal of Pharmacology
2014	Editorial Board, Cardiovascular Research
2014	Top Ten Hypertension Reviewer

As Mentor

2004	Nikhat Salamat, M.D., Best Lung Cancer Poster, CHEST Meeting
2005	Christopher Spradley, M.D., Young Investigator Award, CHEST Meeting
2005	Mazen Kurdi, Ph.D., Young Investigator Best Oral Presentation, 1st Annual Retreat of the Texas A&M University System Health

Science Center Cardiovascular Research Institute

2009 Joshua Burkhart, M1 Medical Student, Recipient: Dean's Summer Medical Research Fellowship

2010 Fouad Zouein, 1st year graduate student, poster award recipient: Model system for investigating the role of transient receptor potential type C channels in angiogenesis.

2011 Carlos Zgheib, 1st place poster at Research Day at the University of Mississippi Medical Center: Zgheib C., Zouein F., Chidiac R., Kurdi M.. Booz G.W. Calyculin A Reveals Serine/Threonine Phosphatase PP1 as a Regulatory Nodal Point in Canonical STAT3 Signaling of Human Microvascular Endothelial Cells.

2011 Fouad Zouein, AHA Scientific Sessions Travel Award–PVD council workshop- Orlando, Florida

2012 Fouad Zouein, School of Health Related Professions Research Day - 1st place award for outstanding research

2012 Fouad Zouein, recipient of a 2012 Research Mini-Fellowship from the Society for Free Radical Biology and Medicine (SFRBM) for his study entitled Cardiac Mitochondrial ROS Production

2013 Fouad Zouein. Junior Initiative Award from the European Cytokine Society for his review article "LIF and the Heart: Just Another Brick in the Wall?" Fouad A. Zouein, Mazen Kurdi, and George W. Booz

2014 Fouad A. Zouein, Ph.D., Regions Graduate Research Award

2014 Venkata Ramana Vaka, recipient of a 2014 Research Mini-Fellowship from the Society for Free Radical Biology and Medicine (SFRBM)

COLLABORATIONS

Roy J. Duhe, Ph.D.
Professor
Department of Pharmacology and Toxicology
The University of Mississippi Medical Center
2008 - 2013

Mazen Kurdi, Ph.D.
Professor
Department of Chemistry and Biochemistry
The Lebanese University
2008 - present

Istvan Arany, Ph.D., C.Sc.
Professor of Pediatrics
Department of Pediatrics, Division of Pediatric Nephrology
University of Mississippi Medical Center
2010 - 2014

Kenneth Liechty, MD
Associate Professor of Pediatric Surgery
Department of Surgery
University of Mississippi Medical Center
2010 - 2012

Nazareno Paolocci, MD, PhD
Assistant Professor of Medicine
Division of Cardiology
Johns Hopkins University
2010 – present

Edward J. Lesnefsky, MD, FACC, FAHA
Division of Cardiology
Professor of Medicine and Biochemistry
Virginia Commonwealth University
Chief, Cardiology Section
McGuire Veterans Affairs Medical Center
Richmond, VA 23249
2014 – present

TEACHING ACTIVITIES (classroom or teaching laboratory)

1974	Cell Physiology Laboratory, University of Pennsylvania Graduate Faculty
1989	Blood Bank Techniques Laboratory, Thomas Jefferson University

The Texas A&M University System Health Science Center
Graduate Faculty and College of Medicine

2003-2007	MPHY 606, Advanced Cardiovascular Biology: Signal Transduction in Heart Failure
2003-2007	MSCI 601, Principles of Medical Science (Part 1): Biomembranes, Membrane Transport
2003-2005	MSCI 689, Advanced Topics in Cell Signaling: G-Protein Receptor Signaling, Cytokine Receptor Signaling
2006	MSCI 612, Current Topics in Cell Signaling: G-Protein Receptor Signaling, Cytokine Receptor Signaling
2004	MPHY 901, Medical Physiology: Adrenal Glands, Hypothalamus/Pituitary Gland, Endocrine Pancreas, Thyroid Gland, Calcium and Phosphate Metabolism
2004-2007	MSCI 602, Principles of Medical Science (Part 2): Thyroid, Endocrine Pancreas, Adrenal Gland and Calcium Regulation
2004	S&W Fellows Course: Cytokines & Heart Failure

Course coordinator

2006	MSCI 612, Current Topics in Cell Signaling

University of Mississippi School of Medicine and School of Graduate Studies in the Health Sciences

Spring 2009 – present	PH652: Advanced Topics in Pharmacology
Fall 2009 – present	PH723: Mechanisms of Drug Action; Cardiovascular Pharmacology (Three 2-hour lectures)
Fall 2009 – present	PH620/722: Introduction To Pharmacology & Therapeutics (Medical Pharmacology): Heart Failure, Vasodilators and Rx of Angina Pectoris (Two 1-hour lectures)
Spring 2010 – present	PH626/726: Pharmacology (Dental)/Fundamental

	Pharmacology: Cardiac Physiology Overview, Heart Failure, Angina
Spring 2010	Pharm 790: Special Topics in Pharmacology and Toxicology (4 credits)
Spring 2016 – present	Research Tools Genomics Technologies PH724: Mitochondria in cell signaling; Approaches for their study, 3 hours
2017 – present	4th Year Pharm Medical Elective

Course coordinator

2014 -2015	PH723: Mechanisms of Drug Action

OTHER TEACHING OR MENTORING ACTIVITIES

Scientific Partner, 2009 – present
The Master's Program in Cardiovascular Pharmacology
The Lebanese University
Beirut, Lebanon

Preclinical Advisor, 2013 – present
3-4 M1 and 3-4 M2 Students

Research Mentor - Pulmonary Fellows, Scott & White Hospital and Cardiovascular Research Institute, Texas A&M College of Medicine

2003 - 2005	Nikhat Salamat, M.D. *Role of STAT Transcription Factors in Apoptosis of Human Non-Small-Cell Lung Cancer Cells*
2003 - 2005	Christopher Spradley, M.D. *Antioncogenic Potential of GRIM-19 in Human Non-Small-Cell Lung Cancer Cells*
2005 - 2006	Gagan Prakash, M.D. *Regulation of Non-Small Cell Cancer Apoptosis by Interferon-γ*

Post-Doctoral Fellows

2004 – 2008	Mazen Kurdi, Ph.D.
2009 – 2011	Thomas Sebastian, Ph.D.
2015	Fouad A. Zouein, Ph.D.
2015 – 2017	Raffaele Altara, Ph.D.

Technicians, Graduate Students, and Summer Students

2000 – 2004	Jonathan Day, B.Sc.	Technician I, II
2003 – 2005	J. Ryan Brewer, B.S.	Technician I
2004 – 2005	Jeremy Nickolai, B.S.	Technician 1
2003	Kelly Culver	Summer Student
5/04 – 1/05	William White	College Student
5/04 – 12/04	Nathan Guthrie	College Student
2004 (fall)	Samantha Bruce	Graduate Student (Rotation)
6/28/07–8/31/07 & 8/1/08–9/18/08	Carlos Zgheib	Masters Student, Holy Spirit University, Lebanon
6/28/07–8/31/07	Marita Faddoul	Masters Student, Holy Spirit University,

		Lebanon
6/28/07–8/31/07	Youssef Bou Assy	Masters Student, Holy Spirit University, Lebanon
8/1/08–9/18/08	Hovig Khachadourian	Undergraduate, Holy Spirit University, Lebanon
1/1/09–7/10/09	Marilyn Burke	Graduate Student, Dept. Pharmacology and Toxicology, University of Mississippi School of Medicine
Summer 2009	Joshua Burkhart	M1 Medical Student, University of Mississippi School of Medicine *The role of SOCS3 in modulating IL-6 type cytokine signaling in mouse coronary endothelial cells*
Summer 2009	Qianli (Lee) Tian	High School Student Summer Undergraduate Research Experience (SURE) participant *Isolating CD34^{+} Stem Cells from Umbilical Cord Blood for Cardiac Repair*
7/2009–8/2010	Fouad Zouein	Research Technician II, University of Mississippi School of Medicine
Summer 2009	Rony Chidiac	Masters Student, Holy Spirit University, Lebanon Summer Undergraduate Research *The Utility of Anti-Oxidant Hydrogels for Stem Cell Delivery to the Heart*
8/2010–11/2013	Fouad Zouein	Graduate Student: Medical Pharmacology, University of Mississippi School of Medicine
08/2009–-2012	Carlos Zgheib	Graduate Student: Medical Pharmacology, University of Mississippi Medical Center
7/8/10–9/23/10	Hani Jamal Alturkmani	3rd year medical student Alfaisal University, College of Medicine
7/1/11–9/23/11	Hani Jamal Alturkmani	4th year medical student Alfaisal University, College of Medicine
	Nour Eddin F. Alshaaer	3rd year medical student Alfaisal University, College of Medicine
6/1/12–8/15/12	Charles Powell	SURE Student University of Mississippi
9/1/11–8/30/12	Kathryn Cooper	Technician I
6/1/13–8/15/13	Charles Powell	SURE Student University of Mississippi
1/1/12–5/1/12	Barak Gunter	Graduate Student, Medical Pharmacology/Psychiatry and Human Behavior
5/5/13–9/15/13 & 5/13/14–9/1/15	Venkata Ramana Vaka	Graduate Student: Medical Pharmacology, University of Mississippi Medical Center

Ph.D. Thesis Advisor

Dr. Carlos Zgheib (2009-2012), "*Regulation of Inflammatory JAK-STAT Signaling: Implications For Cardiac Repair and Remodeling*"

Dr. Fouad Zouein (2010-2013), *"Importance of STAT3 in Hypertension-Induced Remodeling of the Heart*"

Thesis Committees

2007–2008	Joana Dado, Masters The Graduate School of Biomedical Sciences The Texas A&M University System Health Science Center College of Medicine
2009–2012	Chetan Patil, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center
2011–2012	Carlos Zgheib, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center
2012-2013	Fouad A. Zouein, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center
2013	Kandis V. Backus, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center
2014–present	Barak Gunter, Doctoral Student, Psychiatry and Human Behavior School of Graduate Studies in the Health Sciences University of Mississippi Medical Center
2015–present	Xiaochen "Alex" He, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center

TAMHSC Division of Molecular Cardiology Activities

2004 – 2005	Organizer and Chair, Heart and Lung Focus Group

The Texas A&M University System Heath Science Center

2005	Judge, 10th Annual Heath Science Center Research Symposium
2006	Poster Judge, 2nd Annual Cardiovascular Research Institute Retreat
2007	Poster Judge, 3rd Annual Cardiovascular Research Institute Retreat

The University of Mississippi Medical Center

2009	Poster Judge, Research Day, School of Graduate Studies in the Health Sciences
2009 – present	Grants In Progress, Department of Pharmacology and Toxicology
2015	Poster Judge, Research Day, School of Graduate Studies in the Health Sciences

PUBLICATIONS

Citation indices

Citations 3621
h-index 26
i10-index 45

Research Articles

1. Pritchard JB, **Booz G**, Kleinzeller A. Renal sugar transport in the winter flounder. V. Secretion of 2-deoxy-D-galactose. *Am. J. Physiol.* 234: F424-431, 1978.
2. Pritchard JB, **Booz G**, Kleinzeller A. Renal sugar transport in the winter flounder. VI. Reabsorption of D-mannose. *Am. J. Physiol.* 242: F415-422, 1982.
3. Kleinzeller A, Forrest JN, Cha C-J, Goldstein J, **Booz G**. Cell solute composition and potassium effects in slices of the rectal gland of the dogfish shark (*Squalus acanthias*). *J. Comp. Physiol.* 155B: 145-153, 1985.
4. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Taurine and cell volume maintenance in the shark rectal gland: Cellular fluxes and kinetics. *Biochim. Biophys. Acta* 943: 43-52, 1988.
5. Feldman GM, Ziyadeh FN, Mills JW, **Booz GW**, Kleinzeller A. Propionate induces cell swelling and K^+ accumulation in shark rectal gland. *Am. J. Physiol.* 257: C377-C384, 1989.
6. Kleinzeller A, **Booz GW**, Mills JW, Ziyadeh FN. pCMBS-induced swelling of dogfish (*Squalus acanthias*) rectal gland cells: Role of the Na^+,K^+-ATPase and the cytoskeleton. *Biochim. Biophys. Acta* 1025: 21-31, 1990.
7. **Booz GW**, Conrad KM, Hess AL, Singer HA, Baker KM. Angiotensin II binding sites on hepatocyte nuclei. *Endocrinology* 130:3641-3649, 1992.
8. **Booz GW**, Bianchi CP. Stimulation-enhanced 3-O-methylglucose efflux from the frog sartorius: Kinetics and properties of the system. *Biochim. Biophys. Acta* 1109: 132-140, 1992.
9. **Booz GW**, Bianchi CP. 2-Deoxyglucose transport by the frog sartorius: Effects of electrical stimulation and N-carbobenzoxy-glycyl-L-phenylalaninamide. *Comp. Biochem. Physiol.* 106A: 471-477, 1993.
10. Schorb W, **Booz GW**, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. *Circ. Res.* 72: 1245-1254, 1993.
11. **Booz GW**, Dostal DE, Singer HA, Baker KM. Involvement of protein kinase C and Ca^{2+} in angiotensin II-induced mitogenesis of cardiac fibroblasts. *Am. J. Physiol.* 267: C1308-C1318, 1994.
12. **Booz GW**, Taher M, Baker KM, Singer HA. Angiotensin II-induces phosphatidic acid formation in neonatal rat cardiac fibroblasts: Evaluation of the roles of phospholipases C and D. *Mol. Cell. Biochem.* 141: 135-143, 1994.
13. **Booz GW**, Baker KM. Protein kinase C in angiotensin II signalling in cardiac fibroblasts: Role in the mitogenic response. *Ann. N.Y. Acad. Sci.* 752: 158-167, 1995.
14. Thomas WG, Baker KM, **Booz GW**, Thekkumkara TJ. Evidence against a role for protein kinase C in the regulation of the angiotensin II (AT_{1A}) receptor. *Eur. J. Pharmacol.* 295: 119-122, 1996.
15. **Booz GW**, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* 28: 635-640,1996.
16. **Booz GW**, Carl LL, Baker KM. Amplification of angiotensin II signaling in cardiac myocytes by adenovirus-mediated overexpression of the AT1 receptor. *Ann. N.Y. Acad. Sci.* 874: 20-26, 1999.
17. **Booz GW**, Dostal DE, Baker KM. Paracrine actions of cardiac fibroblasts on cardiomyocytes: Implications for the cardiac renin-angiotensin system. *Am. J. Cardiol.* 83:44H-47H, 1999.

18. Dostal DE, **Booz GW**, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and β-adrenergic stimulation. *Basic Res. Cardiol.* 95: 485-491, 2000.
19. Fukuzawa J, **Booz GW**, Hunt RA, Shimizu N, Karoor V, Baker KM, Dostal DE. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. *Hypertension* 35: 1191-1196, 2000.
20. **Booz GW**, Day JNE, Speth R, Baker KM. Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1. *Mol. Cell. Biochem*. 240:39-46, 2002.
21. **Booz GW**, Day NE, Baker KM. Angiotensin II effects on STAT3 phosphorylation in cardiomyocytes: Evidence for Erk-dependent Tyr705 dephosphorylation. *Basic Res. Cardiol.* 98: 33-38, 2003.
22. Steinle JJ, **Booz GW**, Meininger CJ, Day JNE, Granger HJ. β_3-Adrenergic receptors regulate retinal endothelial cell migration and proliferation. *J. Biol. Chem.* 278: 20681-20686, 2003.
23. Kule CE, Karoor V, Day JNE, Thomas WG, Baker KM, Acker KA, **Booz GW**. Agonist-dependent internalization of the angiotensin II type one receptor (AT_1): Role of C-terminus phosphorylation in recruitment of β-arrestins. *Reg. Peptides* 120: 141-148, 2004
24. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, **Booz GW**, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. *Reg. Peptides* 120: 5-13, 2004.
25. Kurdi M, **Booz GW**. Evidence that IL-6-Type Cytokine Signaling in Cardiomyocytes is Inhibited by Oxidative Stress: Parthenolide Targets JAK1 Activation by Generating ROS. *J. Cell. Physiol.* 212: 424-431, 2007
26. Kurdi M, **Booz GW**. Jak1 inhibition, but not STAT1 knockdown, blocks the synergistic IFNγ- and Fas-Induced apoptosis of human non-small cell lung cancer A549 cells. *J. Interferon Cytokine Res.* 27: 16-24, 2007.
27. Kurdi M, Bowers MC, Dado J, **Booz GW**. Parthenolide induces a distinct pattern of oxidative stress in cardiac myocytes. *Free Radic Biol Med.* 42: 474-481, 2007.
28. Kurdi M, Sivakumaran V, Duhé RJ, Aon MA, Paolocci N, **Booz GW**. Depletion of Cellular Glutathione Modulates LIF-Induced JAK1-STAT3 Signaling in Cardiac Myocytes. *Int J Biochem Cell Biol.* 2012;44:2106-15.
29. Arany I, Reed DK, Grifoni SC, Chandrashekar K, **Booz GW**, Juncos LA. A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. *Am J Physiol Renal Physiol* 2012;302:F722-9.
30. Zgheib C, Zouein FA, Chidiac R, Kurdi M, **Booz GW**. Calyculin A Reveals Serine/Threonine Phosphatase PP1 as a Regulatory Nodal Point in Canonical STAT3 Signaling of Human Microvascular Endothelial Cells *J. Interferon Cytokine Res.* 2012;32:87-94
31. Smith JK, Patil CN, Patlolla S, Gunter BW, **Booz GW**, Duhé RJ. Identification of a redox-sensitive switch within the JAK2 catalytic domain. *Free Radic Biol Med* 2012;52:1101-10.
32. Alturkmani HJ, Zgheib C, Zouein FA, Alshaaer NEF, Kurdi M, **Booz GW**. Selenate Enhances STAT3 Transcriptional Activity in Endothelial Cells: Differential Actions of Selenate and Selenite on LIF Cytokine Signaling and Cell Viability *J Inorg Biochem*. 2012;109:9-15.
33. Zgheib C, Kurdi M, Zouein FA, Gunter BW, Stanley BA, Zgheib J, Romero DG, King SB, Paolocci N, **Booz GW**. Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence that STAT3 Signaling is Redox-Sensitive. *PLoS One*. 2012;7:e43313.
34. Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Chronic treatment of mice with leukemia inhibitory

factor does not induce cardiac remodeling but improves heart function. *Eur Cytokine Ne*tw. 2012;23:191-7.
35. Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, Lopez-Ruiz A, Kurdi M, **Booz GW**. Protective Role of STAT3 in Early-Stage Hypertension-Induced Cardiac Remodeling Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation. *Hyper Res* 2013;36:496-503.
36. Werner T, Dombrowski S, Zgheib C, Zouein FA, Keen HL, Kurdi M, **Booz GW**. Elucidating functional context within microarray data by integrated transcription factor focused gene-interaction and regulatory network analysis. *Eur Cytokine Netw* 2013;24:75-90.
37. Zouein FA, Duhé RJ, Arrany I, Shirey K, Hosler JP, Liu H, Saad I, Kurdi M, **Booz GW**. Loss of STAT3 in mouse embryonic fibroblasts reveals its janus-like actions on mitochondrial function and cell viability. *Cytokine* 2014;66:7-16.
38. Zouein FA, Kurdi M, **Booz GW**, Fuseler JW. Applying Fractal Dimension and Image Analysis to Quantify Fibrotic Collagen Deposition and Organization in the Normal and Hypertensive Heart. Microsc Microanal 2014;20:1134-1144.
39. Zeng H, Vaka R, He X, **Booz GW**, Chen JX. High Fat Diet Induces Cardiac Remodeling and Dysfunction: Assessment of the Role Played by SIRT3 Loss. *J Cell Mol Med*. 2015;19:1847-1856.
40. Altara R, Manca M, Hessel MH, Gu Y, van Vark LJ, Akkerhuis M, Staessen JA, Struijker-Boudier HAJ, **Booz GW**, Blankesteijn WM. CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. J Cardiovasc Transl Res. 2016;9:302-14. doi: 10.1007/s12265-016-9703-3. PubMed PMID: 27271043.
41. Altara R, Harmancey R, Didion SP, Booz GW, Zouein FA. Cardiac STAT3 Deficiency Impairs Contractility and Metabolic Homeostasis in Hypertension. Front Pharmacol. 2016;7:436. PubMed PMID: 27899891; PubMed Central PMCID: PMC5110511.

Review Articles

1. Baker KM, **Booz GW**, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. *Ann. Rev. Physiol.* 54: 227-241, 1992.
2. **Booz GW**, Dostal DE, Baker KM. Regulation of cardiac second messengers by angiotensins. In: *Cardiac Renin-Angiotensin System* (1st ed), edited by K. Lindpaintner and D. Ganten. New York: Futura Medical Publishers, 1994, p. 101-124.
3. Dostal DE, **Booz GW**, Baker KM. Cellular and subcellular localization of elements of the cardiac renin-angiotensin system. In: *Cardiac Renin-Angiotensin System* (1st ed), edited by K. Lindpaintner and D. Ganten. New York: Futura Medical Publishers, 1994, p. 1-21.
4. **Booz GW**, Baker KM. Molecular signalling mechanisms controlling the growth and function of cardiac fibroblasts. *Cardiovasc. Res.* 30: 537-543, 1995.
5. Dostal DE, **Booz GW**, Baker KM. Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function. *Mol. Cell. Biochem.* 157: 15-21, 1996.
6. **Booz GW**, Baker KM. Role of the renin-angiotensin system in the pathophysiology of cardiac remodeling. *Blood Pressure* 5 (Suppl 2): 10-18, 1996.
7. **Booz GW**, Baker KM. Actions of angiotensin II on isolated cardiac myocytes. *Heart Failure Reviews* 3: 125-130, 1998.
8. **Booz GW**, Fukuzawa J, Dostal DE, Baker KM. Angiotensin and cytokine receptor crosstalk in modulation of cardiomyocyte hypertrophy. Heart 33:174-179, 2001.

9. **Booz GW**, Day JNE, Baker KM. Interplay between the cardiac renin angiotensin system and JAK-STAT Signaling: Role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. *J. Mol. Cell. Cardiol.* 34:1443-1453, 2002.
10. **Booz GW**. Putting the Brakes on Cardiac Hypertrophy: Exploiting the Intrinsic NO-cGMP Counter-Regulatory System. *Hypertension* 45: 341-346, 2005.
11. Kurdi M, De Mello WC, **Booz GW**. Working outside the system: An update on the unconventional behavior of the renin-angiotensin system components. *Int. J. Biochem. Cell Biol.* 37:1357-1367, 2005.
12. Kurdi M, **Booz GW**. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of IL-6-type cytokine signaling. *J. Cardiovasc. Pharmacol.* 50: 126-141, 2007.
13. **Booz GW**. PARP Inhibitors and Heart Failure: Translational medicine caught in the act. *Congest. Heart Fail*. 13:105-12, 2007.
14. Kurdi M, **Booz GW**. G-CSF-Based Stem Cell Therapy for the Heart – *Unresolved Issues.* Part A: Paracrine Actions, Mobilization, Delivery. *Congest. Heart Fail*. 13: 221-227, 2007.
15. Kurdi M, **Booz GW**. G-CSF-Based Stem Cell Therapy – *Unresolved Issues.* Part B. *Congest. Heart Fail*. 2007;13:347-51
16. Kurdi M, **Booz GW**. JAK redux – A second look at the regulation and role of JAK kinases in the heart. *Am J Physiol Heart Circ Physiol* 2009;297:H1545-56.
17. Kurdi M, Chidiac R, Hoemann C, Zouein F, Zgheib C, **Booz GW**. Hydrogels as a platform for stem cell delivery to the heart. *Congest Heart Failure*. 2010;16(3):132-135.
18. Kurdi M, **Booz GW**. Deciphering STAT3 Signaling In the Heart: Plasticity and Vascular Inflammation. *Congest Heart Failure*. 2010;16:234-238
19. **Booz GW**. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. *Free Radic Biol Med* 2011;51:1054–1061.
20. Kurdi M, **Booz GW**. New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis. *Hypertension* 2011;57:1034-8.
21. Kurdi M, **Booz GW**. Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC. *J Mol Cell Cardiol* 2011;50:964-71.
22. Zouein FA, Duhe RJ, **Booz GW**. JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. *Growth Factors* 2011;29:245-52
23. Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress. *JAK-STAT* 2012;1:102-111.
24. Zouein FA, Zgheib C, Liechty KW, **Booz GW**. Post-Infarct biomaterials, left ventricular remodeling, and heart failure: Is good good enough? *Congest Heart Failure* 2012;18:284-90.
25. Zouein FA, Kurdi M, **Booz GW**. LIF and the Heart: Just Another Brick in the Wall? *Eur Cytokine Netw.* 2013;24:11-9.
26. Zouein FA, Kurdi M, **Booz GW**. Dancing rhinos in stilettos: The amazing saga of the genomic and nongenomic actions of STAT3 in the heart. *JAK-STAT* 2013; 2:e24352.
27. Zouein FZ, de Castro Brás LE, da Costa DV, Lindsey ML, Kurdi M, **Booz GW**. Heart Failure with Preserved Ejection Fraction: Emerging Drug Strategies. *J Cardiovasc Pharmacol* 2013;62:13-21.
28. Zouein FA, **Booz GW**. AAV-Mediated Gene Therapy Cure for Heart Failure: Enhancing Contractility and Calcium Handling. *F1000* 2013;5:27.
29. Altara R, Manca M, Sabra R, Eid AA, **Booz GW**, Zouein FA. Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. *Heart Fail Rev.* 2015 Oct 23. [Epub ahead of print] PubMed PMID: 26498937.
30. Zouein FA, Altara R, Chen Q, Lesnefsky EJ, Kurdi M and **Booz GW**. Pivotal Importance of

STAT3 in Protecting the Heart from Acute and Chronic Stress: New Advancement and Unresolved Issues. *Front Cardiovasc Med* 2015;2:36. doi: 10.3389/fcvm.2015.00036
31. Altara R, Manca M, Brandão RD, Zeidan A, **Booz GW**, Zouein FA. Emerging Importance of Chemokine Receptor CXCR3 and Its Ligands in Cardiovascular Diseases. *Clin Sci (Lond).* 2016;130:463-78.
32. Fan F, Ge Y, Lv W, Elliott MR, Muroya Y, Hirata T, **Booz GW**, Roman RJ. Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Front Biosci (Landmark Ed). 2016;21:1427-1463.
33. Altara R, Mallat Z, Booz GW, Zouein FA. The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. J Immunol Res. 2016;2016:4396368. PubMed PMID: 27795961; PubMed Central PMCID: PMC5066021.
34. Kaplan A, Altara R, Eid A, Booz GW, Zouein FA. Update on the Protective Role of Regulatory T Cells in Myocardial Infarction: A Promising Therapy to Repair the Heart. J Cardiovasc Pharmacol. 2016;68:401-413. PubMed PMID: 27941502.
35. Kaplan A, Abidi E, Ghali R, Kobeissy F, Booz GW, Zouein FA. Functional, Cellular, and Molecular Remodeling of the Heart under Influence of Tobacco Smoke (Under Review).
36. Altara R, Giordano M, Sjaastad-Nordén E, Cataliotti A, Kurdi M, Bajestani SN, Booz GW. Targeting Obesity and Diabetes to Treat HFpEF. Invited review (Submitted).

Editorial Commentaries

1. **Booz GW**. The cardiac angiotensin AT2 receptor, what exactly does it do? *Hypertension*. 43: 1162-1163, 2004.
2. **Booz GW**. Growing old, angiotensin II, cardiac hypertrophy, and death: making the connection with $p66^{Shc}$. *Hypertension* 46: 259-260, 2005.
3. **Booz GW**. Impact of T-Lymphocytes on Cardiac Remodeling in Hypertension: More Questions than Answers. *Hypertension* 2006;48(1):31-2.
4. **Booz GW**. Review of: Heart Failure: Molecules, Mechanisms, and Therapeutic Targets, (Novartis Foundation Symposium 274). *Congest. Heart Failure* 2007;13:62-63.
5. **Booz GW**. Devising New Drugs for the Treatment of Hypertension - “Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond” *J. Cardiovasc. Pharmacol.* 2007;50:1-2.
6. Kurdi M, **Booz GW**. Growing hearts by the bushel. *Congest. Heart Failure* 2008;14:95-96.
7. **Booz GW**. Novel drugs targeting hypertension revisited. *J Cardiovasc Pharmacol.* 2010;56:213-4.
8. Kurdi M, **Booz GW**. Focus on Mitochondria Dysfunction and Dysregulation in Heart Failure: Towards New Therapeutic Strategies to Improve Heart Function. *Congest. Heart Failure* 2011;17:255-6.
9. Zouein FA, Kurdi M, **Booz GW**. HSPA12B and Repairing the Heart: Beauty in Simplicity. *Cardiovasc Res.* 2013;99:587-589.
10. Kurdi M, **Booz GW**. Carvedilol Protects the Infarcted Heart by Upregulating miR-133: First Evidence that Disease State Affects β-Adrenergic Arrestin-Biased Signaling? *J Mol Cell Cardiol.* 2014;76:12-4.
11. Altara R, Booz GW. Deleting Vascular ADAM17 Sheds New Light on Hypertensive Cardiac Hypertrophy. Hypertension. 2016;68:849-50. doi: 10.1161/HYPERTENSIONAHA.116.07715. PubMed PMID: 27480838.
12. Altara R, Didion SP, Booz GW. Conflicting mechanisms of AT2 cardioprotection revealed. Cardiovasc Res. 2016;112:426-8. doi: 10.1093/cvr/cvw199. PubMed PMID: 27659501; PubMed

Central PMCID: PMC5031951.

Book Chapters

1. **Booz GW**, Baker KM. Protein phosphorylation. In. *Hypertension Primer: The Essentials of High Blood Pressure* (2nd ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins, 1999, pp. 71-75.
2. **Booz GW**, Baker KM. Protein phosphorylation. In. *Hypertension Primer: The Essentials of High Blood Pressure* (3rd ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins, 2003, pp. 92-96.
3. **Booz GW**, Baker KM. Intracellular signaling and the cardiac renin angiotensin system. In: De Mello WC, ed. Renin Angiotensin System and the Heart. West Sussex, England: John Wiley & Sons; 2004: 1-17.
4. **Booz GW**. Left ventricular physiology in hypertension. In: *Comprehensive Hypertension*. Editors: Y. H. Lip and J. E. Hall. Mosby, 2007, Chapter 10, pp.113-121.
5. **Booz GW**, Baker KM. Protein phosphorylation. In. *Hypertension Primer: The Essentials of High Blood Pressure* (4th ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins 2008, pp. 16-21.
6. **Booz GW**. Oxidative Stress and Heart Failure: Still a Viable Therapeutic Target? In: García JE, Wright VR eds. *Congestive Heart Failure: Symptoms, Causes and Treatment*. Hauppauge, New York: Nova Science Publishers; 2010: 89-109.

Abstracts

1. **Booz G**, Pritchard JB, Kleinzeller A. The renal clearance of D-mannose in the winter flounder. *Bull. Mt. Desert Isl. Biol. Lab.* 17:44-5, 1977.
2. **Booz G**, Pew DE, Kleinzeller A. The renal handling of D- fructose by the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18: 26, 1978.
3. **Booz G**, Goldstein J, Pritchard J, Kleinzeller A. The handling of D-mannose at the brush border of the kidney in the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18: 26-8, 1978.
4. **Booz G**, Dornbusch J, Goldstein J, Murdaugh A, Forrest JN, Kleinzeller A. Experiments on the cell volume regulation in slices of the rectal gland of the dogfish (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 18:23-5, 1978.
5. **Booz G**. Renal clearance of DMO and methylamine by the winter flounder (*Pseudo-pleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18:25-6, 1978.
6. **Booz G**, Beyenbach K, Kleinzeller A. Methylamine secretion by isolated perfused renal tubules of the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 20: 66-8, 1980.
7. Beyenbach KW, **Booz G**, Kleinzeller A. Transepithelial voltages and resistances across isolated perfused renal tubules of the winter flounder. *Bull. Mt. Desert Isl. Biol. Lab.* 20: 78-82, 1980.
8. Kleinzeller A, Mills JW, **Booz G**, Davis SJ. Effects of p-chloromercuribenzene sulfonate (PCMBS) on the volume maintenance of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 26: 163-4, 1986.
9. Stanley CA, Corkey BE, **Booz G**, Hale DE, Glennon MC, Berry GT. Hepatic acyl CoA profiles in riboflavin-induced multiple acyl-CoA dehydrogenase deficiency. *Pediatr. Res.* 348A, 1987.
10. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Uptake of trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) in skeletal muscle and rectal gland of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 44, 987-88.

11. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Taurine uptake and efflux in rectal gland cells of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 94, 1987-88.
12. Feldman GM, Ziyadeh FN, **Booz GW**, Mills JW, Kleinzeller A. Iso-osmotic cell swelling induced by propionate in rectal gland of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 108-9, 1987-88.
13. **Booz GW**, Ziyadeh FN, Feldman GM, Kleinzeller A. The binding sites involved in p-chloromercuribenzene sulfonate (PCMBS) induced swelling of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 27: 1-3, 1987-88.
14. **Booz GW**, Feldman GM, Mills JW, Kleinzeller A. Cation specificity in cell volume maintenance in rectal gland cells of the dogfish (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 124-5, 1987-88.
15. Feldman GM, Ziyadeh FN, **Booz GW**, Kleinzeller A. Iso-osmotic cell swelling induced by propionate. *Kidney Int.* 33: 418, 1988.
16. Ziyadeh FN, Mills JW, **Booz GW**, Kleinzeller A. Recovery of cell volume and solute composition following potassium-induced swelling in rectal gland cells of the shark (*Squalus acanthias*): Properties of the system. *Bull. Mt. Desert Isl. Biol. Lab.* 28: 68-9, 1989.
17. Feldman GM, Ziyadeh FN, **Booz GW**, Kleinzeller A. Cell swelling induced by an organic anion. *Kidney Int.* 35: 495, 1989.
18. **Booz GW**, Kleinzeller A, Payne J. Hexose transport by dogfish (*Squalus acanthias*) and flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 28: 47, 1989.
19. Kleinzeller A, Ziyadeh FN, **Booz GW**, McCallum S. Role of the Na, K-ATPase in the mercurial-induced swelling of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 29: 67, 1990.
20. **Booz GW**, Kleinzeller A. Hexose transport by flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 29: 52, 1990.
21. **Booz GW**, Bianchi CP. N-Carbobenzoxy-glycyl-L-phenylalaninamide inhibits both basal and contraction-initiated 2-deoxyglucose uptake by frog muscle. *FASEB J.* 4: A541, 1990.
22. **Booz GW**, Kleinzeller A. 2-Deoxyglucose uptake by flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 30: 50, 1991.
23. Kleinzeller A, **Booz GW**, Ziyadeh FN. The effect of medium composition on the anisoosmotic volume response of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 30: 76-77, 1991.
24. **Booz G**, Shetlar R, Morrison-Shetlar A. Anoxia affects the membrane cytoskeleton of flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 31: 14-15, 1992.
25. **Booz GW**, Conrad KM, Hess AL, Baker KM. Angiotensin II binding sites on hepatocyte nuclei. *FASEB J.* 6: A1577, 1992.
26. Schorb W, **Booz GW**, Dostal DE, Chang KC, Baker KM. Angiotensin II receptor mediated growth of cardiac fibroblasts. *Circulation* 86: A189, 1992.
27. Thekkumkara TJ, Du J, Dostal DE, **Booz GW**, Motel TJ, Baker KM. Characterization of permanently transfected AT_{1A} receptors in CHO-K1 cells: Desensitization by angiotensin II. *FASEB J.* 7: A491, 1993.
28. **Booz GW**, Singer HA, Baker KM. Role of protein kinase C in angiotensin II-induced mitogenesis of neonatal rat cardiac fibroblasts. *The Physiologist* 36:A-11, 1993.
29. Taher MM, **Booz GW**, Baker KM, Singer HA. Angiotensin-induced phosphatidic acid in cardiac fibroblasts. *J. Mol. Cell. Cardiol.* 26: CLV(Abstr. #19), 1994.
30. **Booz GW**, Reiprish MJ, Baker KM. AT2 receptor blockade augments angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* 26: 547 (#61), 1995.
31. Lin C, Baker KM, Rothblum KN, **Booz GW**, Dostal DE. Atrial natriuretic peptide regulation of renin and angiotensinogen mRNA in cultured rat ventricular cardiac fibroblasts. *Hypertension* 26: 562 (#P64), 1995.

32. Fukuzawa J, Dostal DE, **Booz GW**, Hunt RA, Kempinski AM, Baker KM. Cardiotrophin-1 induces cardiomyocyte hypertrophy through stimulation of the renin-angiotensin system. *J. Am. Coll. Cardiol.* 2 (Suppl A):315A, 1999.
33. **Booz GW**, Smith JD, Baker KM. Angiotensin II inhibits gp130 signaling in cardiac myocytes by tyrosine phosphatase activation. *J. Am. Coll. Cardiol.* 37 (Suppl A): 239A, 2001.
34. Fukuzawa J, Baker KM, **Booz GW**. Negative modulation of angiotensin II-induced Jak/STAT signaling in cardiomyocytes via stable complex formation of protein tyrosine phosphatase SHP-2 with STAT3. *J. Am. Coll. Cardiol.* 37 (Suppl A): 295A, 2001.
35. **Booz GW**, Day JNE, Baker KM. Endothelin-1 inhibits activation of the LIF receptor in cardiomyocytes. *Hypertension* 38: 529 (P219), 2001.
36. Kule CE, Karoor V, Day JNE, Thomas WG, Baker KM, Acker KA, **Booz GW**. Rescue of internalization-impaired angiotensin II AT_1 mutants by β-arrestin overexpression. *J. Am. Coll. Cardiol.* 43 (Suppl A): 455A, 2004.
37. Salamat N, Maxwell SA, Brewer JR, Day JNE, Winn RE, **Booz GW**. Activation of STAT1 BY IFN-γ Inhibits Growth of Human Non-Small Cell Lung Cancer Cells. *Chest* 126 : 914S, 2004.
38. Day JNE, **Booz GW**. The Anti-Inflammatory Agent Parthenolide has Differential and Independent Effects on Jak-STAT and ERK Signaling in Cardiac Myocytes. *Hypertension* 44 (Oct): P9, 2004.
39. Day JNE, **Booz GW**. Molecular mechanisms of IL-6-related-cytokine STAT3 regulation in cardiac myocytes. *J Cardiac Failure* 10 (Suppl 4): 121, 2004.
40. Brewer JR, Guthrie NS, **Booz GW**. Interferon-γ has a potent cytostatic effect via STAT1 activation on the A549 human lung cancer cell line. *Mol Cell Biol* 15: 370a (#2047), 2004.
41. Kurdi M, Nickolai JL, **Booz GW**. Anti-inflammatory parthenolide inhibits JAK1 activation in cardiac myocytes but induces oxidative stress. *J. Mol. Cell. Cardiol.* 38: 845 (#99), 2005.
42. Brewer JR, Spradley C, Nickolai JL, Winn RE, **Booz GW**. Role of STAT1 in the Permissive Effect of Interferon-γ on FAS-Induced Apoptosis of Non-Small Cell Lung Cancer Cells. *Chest* 128: 154S, 2005.
43. Bowers M, Kurdi M, Nickolai JL, **Booz GW**. Parthenolide induces oxidative stress in cardiomyocytes: Dfferential activation of mitochondrial and NADPH oxidases. *J Cardiac Failure* 11 (Suppl 6): 070, i2005.
44. Prakash G, **Booz GW**. Role for STAT3 in apoptosis signaling by interferon-γ in human nonsmall cell lung cancer A549 cells. *Proc Am Thorac Soc* 3 (Abstract Issue), A175, 2006.
45. Kurdi M, **Booz GW**. Inhibition of IL-6-type cytokine signaling by oxidative stress in cardiac myocytes. *J. Mol. Cell. Cardiol.* 40: 883 (#95), 2006.
46. Kurdi M, **Booz GW**. Oxidative stress blocks activation of JAK-STAT signaling in cardiac myocytes. *J. Mol. Cell. Cardiol.* 42(S1):S50, 2007.
47. Zgheib C, Sebastian T, Tocchetti CG, Paolocci N, King SB, Kurdi M, **Booz GW**. Nitroxyl activates redox-sensitive stress signaling in endothelial cells and has anti-inflammatory actions. *Hypertension* 2010;56:P351.
48. Zgheib C, Sebastian T, Chidiac R, Keen HL, Kurdi M, **Booz GW**. Protein phosphatase 2A (PP2A) plays a critical role determining the endothelial cell gene expression profile of leukemia inhibitory factor (LIF). *Hypertension* 2010;56:O31.
49. Alturkmani HJ, Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Sodium Selenate Enhances Endothelial Cell STAT3 Tyrosine Phosphorylation and DNA Binding. Mol. Biol. Cell 2010;21:4299 (#2971/L077).
50. Zouein FA, Sebastian T, Farley JM, **Booz GW**. Transient Receptor Potential Type C Channels Play a Critical Role in Angiogenesis. FASEB J 2011;25:1091.12
51. Allukian M, Herdrich BJ, Xu J, Wu W, Dorsett-Martin W, **Booz G**, Mitchell ME, Gorman JH, Gorman RC, Liechty KW. Decreased Inflammation During Cardiac Regeneration Following Fetal Myocardial Infarction (MI) Is Associated with Decreased NF-κB Expression Compared

to the Adult. American College of Surgeons' 97th Annual Clinical Congress
52. Arany I, Reed D, Grifoni SC, **Booz G**, Juncos LA. A novel U-STAT3-dependent regulation of TGFβ1-induced renal tubular epithelial-mesenchymal transition by chronic nicotine exposure. The American Society of Nephrology 2011.
53. Arany I, Clark K, Reed D, **Booz G**, Juncos LA Sex hormones modulate responses to oxidative stress in renal proximal tubule cells. 2011 APS Conference: Physiology of Cardiovascular Disease: Gender Disparities.
54. Zouein FA, Zgheib C, Hamza S, Hall JE, Ruiz A, Juncos L, **Booz GW**. DUAL ROLE OF STAT3 IN HYPERTENSION-INDUCED CARDIAC REMODELING. The FASEB Journal. 2012;26:1060.19.
55. Zouein F, Zgheib C, Fuseler J, Hall JE, Kurdi M, **Booz GW**. STAT3 Affects Myofibrillar Structure and Its Loss May Contribute to Heart Failure in Hypertension. Hypertension. 2012;60:A71.
56. Zgheib C, Kurdi M, Zouein F, Zgheib J, King S, Paolocci N, **Booz GW**: Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling is Redox-Sensitive. Hypertension. 2012;60:A219
57. Fuseler JW, Zouein FA, Kurdi M, **Booz GW**. Fractal and Image Analysis of Collagen Fibrosis in Hypertensive Induced Myocardial Remodeling in Mouse Hearts Lacking STAT3 Protection. Microscopy & Microanalysis. 2013
58. Zouein FA, Kurdi M, **Booz GW**, Fuseler JW. Role of STAT3 in Collagen Deposition and Organization in the Normal and Hypertensive Heart. Hypertension. 2013;62:A387. Abstract. Available at: http://hyper.ahajournals.org/cgi/content/meeting_abstract/62/3_MeetingAbstracts/A387.
59. Zouein FA, Zgheib C, do Carmo JM, Vaka R, Altara R, Kurdi M, **Booz G**. Abstract 110: Importance of the C-Terminal Transactivation Domain of STAT3 in Hypertension-Induced Cardiac Hypertrophy. Hypertension. 2015;66:A110. Available: http://hyper.ahajournals.org/content/66/Suppl_1